Strategic Diagnostics Inc. Announces Success in Demonstrating Utility of its Proprietary Genomic Antibodies(TM) Reagents on Clinical Samples in Cooperation with the Human Protein Atlas

NEWARK, Del.--(BUSINESS WIRE)--Strategic Diagnostics Inc. (Nasdaq:SDIX) - today announced the successful use of a number of its antibody reagents on clinical samples in studies being conducted by the Swedish Human Protein Atlas (HPA) program of the Human Proteome Resource (HPR) Center located in Stockholm, Sweden. The reagents, produced using SDI’s proprietary Genomic Antibodies™ technology, specifically target a selection of cancer associated proteins. The antibodies were studied in the HPA’s tissue-profiling program and generated high-resolution immunohistochemistry images across a wide spectrum of normal and cancerous tissues. Analyses of immunohistochemistry images are standard tests performed by pathology laboratories to diagnose disease. For each antibody, 576 spots of human tissue from 360 different individuals were treated and stained.